The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Q1 2025 Management View CEO Matthew Gline described the quarter as "relatively quiet" ahead of an "exciting, busy fall," highlighting three main themes: progress with IMVT-1402 and Immunovant's ...

Unlike BioNTech, Moderna's pipeline is nearly "all in" on mRNA assets. Most of them are infectious disease vaccines, particularly in COVID, flu, and RSV.

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday.

BioNTech SE BNTX and Moderna Inc MRNA are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic. Also Read: FDA Approves Updated ...

Shares of Moderna and BioNTech rose on Monday after two tantalizing morsels hinted at their potential for attacking cancer. Cancer treatment is one of the pharmaceutical industry’s biggest, most ...